Last Updated: 26 Aug 2025
Source: Statifacts
In Vitro Diagnostic (IVD) Reagents Market (By Type: Immune Diagnosis, Clinical and Biochemical, Molecular Diagnosis, POCT, and Other; By Application: Hospital, Laboratory, and Other; By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Industry Size, Share, Growth, Trends 2025 to 2034.
The global in vitro diagnostic (IVD) reagents market size surpassed USD 42.51 billion in 2024 and is predicted to reach around USD 71.93 billion by 2034, registering a CAGR of 5.4% from 2025 to 2034.
-reagents-market.webp "In Vitro Diagnostic (IVD) Reagents Market Size 2025 to 2034")
| Reports Attributes | Statistics |
| Market Size in 2024 | USD 42.51 Billion |
| Market Size in 2025 | USD 44.81 Billion |
| Market Size in 2031 | USD 61.43 Billion |
| Market Size by 2034 | USD 71.93 Billion |
| CAGR 2025 to 2034 | 5.4% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
The in vitro diagnostic (IVD) reagents market is experiencing strong growth is due to several trends. An expansion in spending on molecular diagnostics and genetic testing is boosting demand for advanced reagents in precision medicine. The growing use of point-of-care testing reagents, enabling faster and more accessible diagnostics. Artificial intelligence and automation in laboratory setups is improving the speed of testing and also the quality of testing. The market for in vitro diagnostic reagents is also seeing high demand due to testing required during personalized medicine and companion diagnostics, requiring specialized reagents tailored to individual patient profiles. The adoption of liquid biopsy and non-invasive testing methods is expanding reagent requirements.
Two main drivers are the high demand in in vitro diagnostic testing required with a growing global risk of infectious and chronic diseases and the global emphasis on early and accurate disease detection. Despite this, obstacles to growth such as the complicated and expensive manufacturing setups required for advanced diagnostic tests and reagent development, are limiting accessibility in resource-constrained settings. Looking ahead, opportunities include the expansion of diagnostic services in emerging markets with improving healthcare infrastructure and the increasing demand for home-based and self-testing kits, opening new pathways for reagent innovation and commercialization.
| Regions | Shares (%) |
| North America | 40% |
| Asia Pacific | 30% |
| Europe | 20% |
| LAMEA | 10% |
| Segments | Shares (%) |
| Immune Diagnosis | 25% |
| Clinical and Biochemical | 30% |
| Molecular Diagnosis | 20% |
| POCT (Point-of-Care Testing) | 18% |
| Other | 7% |
| Segments | Shares (%) |
| Hospital | 50% |
| Laboratory | 40% |
| Other | 10% |
Published by Vidyesh Swar
